Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1352W HIGH $2.89
Volume
229.16 K
Value Traded
3.18 M
Short % Float
2.21%
-1.09%Week
-8.59%1 Month
+17.53%3 Month
+32.12%6 Month
-96.18%5 Year
-96.13%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
77.74 M
EPS (TTM)
-1.12
P/E Ratio
-
Ent. Value
59.53 M
Total Shares
42.95 M
Float Shares
38.45 M
Insiders
10.48%
Institutions
61.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LUNG Catalyst Timeline
Dated clinical, regulatory and corporate events for Pulmonx Corporation
Past FDA Catalysts and PDUFA Decisions
How LUNG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
2
Drugs Scored
-
rNPV / MCap
Top 91%
Micro Cap(rank 599 of 658)
Percentile Rank
Pulmonx Corporation faces pipeline headwinds (22/100), with 2 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every LUNG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Radhakrishnan SrikanthOfficer (Chief Science & Techn. Officer) | Sell | -2,643 328,596 held | $2.26 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LUNG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.1 % (-50 %) | 3.62 M | 2.79 M | 36.79% ( 750.00 K) |
LUNG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LUNG ranks across every disease it competes in
Competitive Position is a premium feature
See how LUNG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLUNG News
LUNGPulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue
Pulmonx Corporation announced the reappointment of Glen French as President and CEO alongside Derrick Sung as COO and CFO as part of a management transition. The company provided a preliminary revenue estimate of approximately $21.5 million for the third quarter of 2025 while rescheduling the official earnings call to November 12, 2025. The resignations of former executives Steve Williamson and Mehul Joshi were confirmed, but the company emphasized that these resignations were not due to disagreements. The company aims to stabilize and enhance shareholder value moving forward.
Read more →LUNG▼ -6.8%on this news
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer Redwood City, CA
Pulmonx Corporation has appointed Mehul Joshi as Chief Financial Officer, effective April 3, 2024. Joshi succeeds John McKune, who served as Interim CFO since October 2023. With over 30 years of experience in finance, Joshi aims to leverage his skills to advance Pulmonx's growth strategies, specifically in expanding access to the company's Zephyr Valve treatment for patients with severe emphysema. The transition signifies Pulmonx's commitment to strengthening its leadership team during a pivotal time for the company.
Read more →LUNGPulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief F
Pulmonx Corporation announced a transition in its Chief Financial Officer position, with Derrick Sung stepping down to pursue another opportunity. John McKune has been appointed as Interim CFO to ensure a smooth transition. The company also revealed preliminary third quarter 2023 revenue of approximately $17.6 million, reflecting a 30% increase from the same period last year. The final financial results will be reported at a conference call scheduled for October 30, 2023.
Read more →About Pulmonx Corporation
Headquarters700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
BIOPHARMAWATCH ELITE PLUS
Trade the next LUNG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime